MIRA Pharmaceuticals, Inc. has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-an anxiety treatment, increased cognition and without the increased appetite associated with THC. The simulations on MIRA1a were conducted in conjunction with the Company's strategic collaboration with InSilicoTrials, a company specializing in leveraging AI and simulations to enhance drug and medical device development. Decoding MIRA1a's Potential: A Possible Breakthrough in Anxiety, Appetite, and Cognition: Through meticulous computer-aided simulations, researchers have uncovered MIRA1a's predicted ability to initiate a response at three pivotal receptors in the brain-- Serotonin 1a (5-HT1a), Serotonin 2c (5-HT2c), and Dopamine D1 receptors.

Unlocking Anxiety Relief: 5-HT1a Receptor Activation: The simulations suggest that MIRA1a's agonistic action on the 5-HT1a receptor aligns with established anxiolytic properties in medications like Buspirone and certain SSRIs. This finding could potentially result in providing a new therapy for anxiety disorder interventions by addressing disrupted signaling associated with this receptor. Battling Appetite Concerns: 5-HT2c Receptor Modulation: The in silico analysis reveals MIRA1a's interaction with the 5-HT2c receptor, suggesting its potential to avoid the appetite related side effects often linked to THC.

Drawing parallels with Lorcaserin, known for its FDA approved appetite-suppressing effects, MIRA1a stands out as a potentially viable solution for those seeking neuropharmacological relief from anxiety and cognitive impairment without the side effect of an increase in appetite that accompanies THC. Cognitive Enhancement: Dopamine D1 Receptor Activation: MIRA1a's engagement with the Dopamine D1 receptor suggests a potential pathway for cognitive enhancement. With the potential to influence learning and memory, MIRA1a's activation of the D1 receptor may pave the way for novel interventions in disorders associated with cognitive impairment.